Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection

Biomarkers in Medicine

Volumn 5, Issue 2, 2011, Pages 171-186

  Lichtfuss, Gregor F ^a,b   Hoy, Jennifer ^b,c   Rajasuriar, Reena ^a,b,d   Kramski, Marit ^e   Crowe, Suzanne M ^a,b,c   Lewin, Sharon R ^a,b,c  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

antiretroviral therapy; HIV; immune activation; immune dysfunction; immune senescence; microbial translocation; non AIDS illness

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD30 ANTIGEN; CD38 ANTIGEN; CD69 ANTIGEN; COMBINATION ANTIRETROVIRUS AGENT; D DIMER; DIPEPTIDYL PEPTIDASE IV; DNA 16S; ENDOTOXIN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS RNA;

ARTICLE; BONE DISEASE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE COURSE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER DISEASE; MONOCYTE; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTI-HIV AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM;

EID: 79953892744     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.11.15     Document Type: Article

References (161)

1. Kahn JO, Walker BD: Acute human immunodefciency virus type 1 infection. N. Engl. J. Med. 339(1), 33-39 (1998).
2. + T lymphocytes from effector sites in the gastrointestinal tract. J. Experiment. Med. 200(6), 761-770 (2004). (Pubitemid 39299462)
3. Brenchley JM, Price DA, Schacker TW et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006). (Pubitemid 44924494)
4. Sodora D, Silvestri G: Immune activation and AIDS pathogenesis. AIDS 22(4), 439-446 (2008). (Pubitemid 351317285)
5. Palella FJ, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodefciency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998). (Pubitemid 28135961)
6. Collaboration ATC: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative ana lysis of 14 cohort studies. Lancet 372(9635), 293-299 (2008).
7. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J. Acquir. Immune Defc Syndr. 46(1), 72-77 (2007). (Pubitemid 47514615)
8. Lohse N, Hansen A-BE, Pedersen G et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 146(2), 87-95 (2007). (Pubitemid 351640011)
9. Collaboration ATC: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative ana lysis of 13 HIV cohort studies. Clin. Infect. Dis. 50(10), 1387-1396 (2010).
10. Smith C; Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group: Factors associated with specifc causes of death amongst HIV-positive individuals in the D:A:D Study AIDS 24(10), 1537-1548 (2010).
11. Volberding PA, Deeks SG: Antiretroviral therapy and management of HIV infection. Lancet 376(9734), 49-62 (2010).
12. Nixon DE, Landay AL: Biomarkers of immune dysfunction in HIV. Curr. Opin. HIV AIDS 5(6), 498-503 (2010).
13. Santis AG, Campanero MR, Alonso JL et al.: Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway Eur. J. Immunol. 22(5), 1253-1259 (1992).
14. Thèze J, Alzari PM, Bertoglio J: Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today 17(10), 481-486 (1996).
15. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF: Discrete stages of human intrathymic differentiation: ana lysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad. Sci. USA 77(3), 1588-1592 (1980). (Pubitemid 10073807)
16. Krowka JF, Cuevas B, Maron DC, Steimer KS, Ascher MS, Sheppard HW: Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. J. Acquir. Immune Defc Syndr. Hum. Retrovirol. 11(1), 95-104 (1996).
17. Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T-cell subsets in HIV-1 disease. Scand. J. Clin. Lab. Invest. 68(3), 233-241 (2008). (Pubitemid 351630826)
18. + regulatory T cells control T-cell responses to human immunodefciency virus and cytomegalovirus antigens. J. Virol. 78(5), 2454-2459 (2004). (Pubitemid 38228938)
19. + regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad. Sci. USA 107(23), 10632-10637 (2010).
20. + cytotoxic T cells express CD38 and HLA-DR antigens. J. Immunol. 150(7), 3070-3079 (1993). (Pubitemid 23127556)
21. + T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J. Acquir. Immune Defc Syndr. 6(8), 904-912 (1993). (Pubitemid 23207458)
22. Coetzee L, Tay S, Lawrie D, Janossy G, Glencross D: From research tool to routine test: CD38 monitoring in HIV patients. Cytometry B Clin Cytom. 76(6), 375-384 (2009).
23. Giorgi JV, Hultin LE, McKeating JA et al.: Shorter survival in advanced human immunodefciency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179(4), 859-870 (1999). (Pubitemid 29159331)
24. Cao W, Jamieson BD, Hultin LE, Hultin PM, Detels R: Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res. Hum. Retroviruses 25(2), 183-191 (2009).
25. + T-cell changes independent of viral load. Blood 104(4), 942-947 (2004). (Pubitemid 39038012)
26. Kalayjian RC, Machekano RN, Rizk N et al.: Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy J. Infect. Dis. 201(12), 1796-1805 (2010).
27. + T cell gains in human immunodefciency virus-infected patients with sustained viral suppression during antiretroviral therapy J. Infect. Dis. 187(10), 1534-1543 (2003). (Pubitemid 36578959)
28. Solomon A, Cameron PU, Bailey M et al.: Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J. Infect. Dis. 187(12), 1915-1923 (2003). (Pubitemid 36724490)
29. + T-cell activation and senescence but not with lower effector memory T-cell function. Clin. Immunol. 120(2), 163-170 (2006). (Pubitemid 44080682)
30. + T cell recovery and mortality in HIV-infected Ugandans initiating ART Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
31. Scheel-Toellner D, Richter E, Toellner KM et al.: CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-γ. Lab. Invest. 73(5), 685-690 (1995).
32. Chilosi M, Facchetti F, Notarangelo LD et al.: CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition. Eur. J. Immunol. 26(2), 329-334 (1996). (Pubitemid 26060237)
33. Mavalia C, Scaletti C, Romagnani P et al.: Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 151(6), 1751-1758 (1997). (Pubitemid 27527937)
34. Keane NM, Price P, Lee S, Stone SF, French MA: An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy Clin. Exp. Immunol. 126(1), 111-116 (2001). (Pubitemid 32989499)
35. Hosono O, Homma T, Kobayashi H et al.: Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin. Immunol. 91(3), 283-295 (1999). (Pubitemid 29250214)
36. Lambeir A-M, Durinx C, Scharpé S, De Meester I: Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40(3), 209-294 (2003). (Pubitemid 36775376)
37. Pizzolo G, Vinante F, Nadali G et al.: High serum level of soluble CD30 in acute primary HIV-1 infection. Clin. Exp. Immunol. 108(2), 251-253 (1997). (Pubitemid 27223461)
38. Pizzolo G, Vinante F, Morosato L et al.: High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 8(6), 741-745 (1994). (Pubitemid 24163414)
39. Rizzardi GP, Barcellini W, Tambussi G et al.: Plasma levels of soluble CD30, tumour necrosis factor (TNF)-α and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 10(13), F45-F50 (1996). (Pubitemid 26370657)
40. Mostafa H-M-H, Ali-Akbar P, Zahra S et al.: Soluble CD26 and CD30 plasma levels in HIV infected patients with and without GB virus type C co-infection. Pak. J. Biol. Sci. 10(12), 2014-2019 (2007). (Pubitemid 47056171)
41. Sadeghi M, Süsal C, Daniel V et al.: Short communication: decreasing soluble CD30 and increasing IFN-γ plasma levels are indicators of effective highly active antiretroviral therapy AIDS Res. Hum. Retroviruses 23(7), 886-890 (2007). (Pubitemid 47267495)
42. Regidor DL, Detels R, Breen EC et al.: Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and infammation. AIDS 25(3), 303-314 (2011).
43. Biswas P, Cozzi-Lepri A, Delfanti F et al.: Signifcant link between sCD30 changes and HIV viremia in patients treated with HAART. J. Med. Virol. 78(12), 1513-1519 (2006). (Pubitemid 44672491)
44. Widney D, Gundapp G, Said JW et al.: Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin. Immunol. 93(2), 114-123 (1999). (Pubitemid 29523387)
45. Messele T, Brouwer M, Girma M et al.: Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers. Clin. Immunol. 98(2), 212-219 (2001).
46. + T-cell counts. Clin. Diagn. Lab. Immunol. 9(3), 558-561 (2002). (Pubitemid 34538213)
47. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, Study SHC: Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodefciency virus type 1. J. Infect. Dis. 185(4), 456-462 (2002). (Pubitemid 34142807)
48. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355(22), 2283-2296 (2006).
49. Kuller LH, Tracy R, Belloso W et al.: Infammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5(10), e203 (2008).
50. Rodger AJ, Fox Z, Lundgren JD et al.: Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J. Infect. Dis. 200(6), 973-983 (2009).
51. Baker JV, Neuhaus J, Duprez D et al.: Changes in infammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J. Acquir. Immune Defc Syndr. 56(1), 36-43 (2011).
52. Neuhaus J, Jacobs DR, Baker JV et al.: Markers of infammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 201(12), 1788-1795 (2010).
53. Phillips AN, Carr A, Neuhaus J et al.: Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir. Ther. (Lond.) 13(2), 177-187 (2008). (Pubitemid 351535369)
54. Sandler NG, Wand H, Roque A et al.: Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203(6), 780-790 (2011).
55. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to infammation. N. Engl. J. Med. 340(6), 448-454 (1999). (Pubitemid 29084777)
56. Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ: C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin. Chem. 55(2), 239-255 (2009).
57. Luc G, Bard J-M, Juhan-Vague I et al.: C-reactive protein, interleukin-6, and fbrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler. Thromb. Vasc Biol. 23(7), 1255-1261 (2003). (Pubitemid 36871282)
58. Lau B, Sharrett AR, Kingsley LA et al.: C-reactive protein is a marker for human immunodefciency virus disease progression. Arch. Intern. Med. 166(1), 64-70 (2006). (Pubitemid 43063843)
59. Triant VA, Meigs JB, Grinspoon SK: Association of C-reactive protein and HIV infection with acute myocardial infarction. J. Acquir. Immune Defc Syndr. 51 (3), 268-273 (2009).
60. Chaudhary M, Kashyap B, Gautam H, Saini S, Bhalla P: Role of C-reactive protein in HIV infection: a pilot study Viral Immunol. 21(2), 263-266 (2008). (Pubitemid 351873362)
61. van Vonderen MGA, Hassink EAM, van Agtmael MA et al.: Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy J. Infect. Dis. 199(8), 1186-1194 (2009).
62. + cell rises in HIV-infected patients. PLoS One 5(10), e13188 (2010).
63. Shikuma CM, Ribaudo HJ, Zheng Y et al.: Change in high-sensitivity C-reactive protein (hsCRP) levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res. Hum. Retroviruses (2010) (Epub ahead of print).
64. Ross AC, Rizk N, O'Riordan MA et al.: Relationship between infammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy Clin. Infect. Dis. 49(7), 1119-1127 (2009).
65. Kishimoto T: Interleukin-6: from basic science to medicine-40 years in immunology Ann. Rev. Immunol. 23, 1-21 (2005). (Pubitemid 40563163)
66. Franceschi C, Capri M, Monti D et al.: Infammaging and anti-infammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 128(1), 92-105 (2007). (Pubitemid 46073065)
67. Harris TB, Ferrucci L, Tracy RP et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106(5), 506-512 (1999). (Pubitemid 29231100)
68. Baker J, Quick H, Hullsiek KH et al.: Interleukin-6 and D-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med. 11(9), 608-609 (2010).
69. Jong E, Louw S, Meijers JCM et al.: The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy AIDS Patient Care STDS 23(12), 1001-1007 (2009).
70. Cohen HJ, Harris T, Pieper CF: Coagulation and activation of infammatory pathways in the development of functional decline and mortality in the elderly Am. J. Med. 114(3), 180-187 (2003). (Pubitemid 36294002)
71. Calmy A, Gayet-Ageron A, Montecucco F et al.: HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23 (8), 929-939 (2009).
72. Duprez DA, Kuller LH, Tracy R et al.: Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 207(2), 524-529 (2009).
73. Funderburg NT, Mayne E, Sieg SF et al.: Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115(2), 161-167 (2010).
74. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200(6), 749 (2004).
75. Estes J, Baker JV, Brenchley JM et al.: Collagen deposition limits immune reconstitution in the gut. J. Infect. Dis. 198(4), 456-464 (2008).
76. + T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 3(2), 172-181 (2010).
77. Jiang W, Lederman MM, Hunt P et al.: Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199(8), 1177-1185 (2009).
78. Brenchley J: Microbial translocation and T cell dysfunction. Presented at: 4th International AIDS Society Conference. Sydney, Australia, 22-25 June 2007 (Abstract TUSY402).
79. Villar J, Pérez-Méndez L, Espinosa E et al.: Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One 4(8), e6818 (2009).
80. Hurley JC: Endotoxemia: methods of detection and clinical correlates. Clin. Microbiol. Rev. 8(2), 268-292 (1995).
81. Thomas LL, Sturk A, Kahlé LH, ten Cate JW: Quantitative endotoxin determination in blood with a chromogenic substrate. Clin. Chim. Acta 116(1), 63-68 (1981). (Pubitemid 11060004)
82. Novitsky TJ, Roslansky PF, Siber GR, Warren HS: Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate. J. Clin. Microbiol. 21(2), 211-216 (1985). (Pubitemid 15161115)
83. Rajasuriar R, Booth D, Solomon A et al.: Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J. Infect. Dis. 202(8), 1254-1264 (2010).
84. Anselmi A, Vendrame D, Rampon O, Giaquinto C, Zanchetta M, De Rossi A: Immune reconstitution in human immunodefciency virus type 1-infected children with different virological responses to anti-retroviral therapy Clin. Exp. Immunol. 150(3), 442-450 (2007). (Pubitemid 350098747)
85. Cassol E, Malfeld S, Mahasha P et al.: Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy J. Infect. Dis. 202(5), 723-733 (2010).
86. Trøseid M, Nowak P, Nyström J, Lindkvist A, Abdurahman S, Sönnerborg A: Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy AIDS 24(11), 1733-1737 (2010).
87. Lester RT, Yao X-D, Ball TB et al.: HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS One 4(5), e5644 (2009).
88. Redd AD, Dabitao D, Bream JH et al.: Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad. Sci. USA 106(16), 6718-6723 (2009).
89. Miller MA, McTernan PG, Harte AL et al.: Ethnic and sex differences in circulating endotoxin levels: a novel marker of atherosclerotic and cardiovascular risk in a British multi-ethnic population. Atherosclerosis 203(2), 494-502 (2009).
90. Opal SM, Scannon PJ, Vincent JL et al.: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J. Infect. Dis. 180(5), 1584-1589 (1999). (Pubitemid 29506461)
91. Ancuta P, Kamat A, Kunstman KJ et al.: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 3 (6), e2516 (2008).
92. Cross AS, Opal SM, Warren HS et al.: Active immunization with a detoxifed Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J. Infect. Dis. 183(7), 1079-1086 (2001). (Pubitemid 32230956)
93. Titanji K, De Milito A, Cagigi A et al.: Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108(5), 1580-1587 (2006). (Pubitemid 44316125)
94. Lien E, Aukrust P, Sundan A, Müller F, Frøland SS, Espevik T: Elevated levels of serum-soluble CD14 in human immunodefciency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92(6), 2084-2092 (1998). (Pubitemid 28446698)
95. Wallet MA, Rodriguez CA, Yin L et al.: Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy AIDS 24(9), 1281-1290 (2010).
96. Hamann L, Alexander C, Stamme C, Zähringer U, Schumann RR: Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms. Infect. Immun. 73(1), 193-200 (2005). (Pubitemid 40041109)
97. Fan H, Cook JA: Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10(2), 71-84 (2004).
98. + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy AIDS 22(15), 2035-2038 (2008).
99. + subjects with <50 copies/ml HIV-1 RNA. J. Clin. Virol. 46 (4) 367-370 (2009).
100. Kitchens RL, Thompson PA: Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J. Endotoxin Res. 11(4), 225-229 (2005). (Pubitemid 41358857)
101. Balagopal A, Philp FH, Astemborski J et al.: Human immunodefciency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135(1), 226-233 (2008). (Pubitemid 351899010)
102. Crane M, Rajasuriar R, Avahingsanon A et al.: LPS, immune activation and liver disease in HIV-HBV co-infection and the effects of HBV-active HAART. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-22 March 2011.
103. Robbins GK, Spritzler JG, Chan ES et al.: Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin. Infect. Dis. 48(3), 350-361 (2009).
104. + patients with various CD4 nadir counts. Microbes Infect. 12(5), 374-381 (2010).
105. Hunt P, Sinclair E, Epling L et al.: T cell senescence and proliferation defects persist in treated HIV-infected individuals maintaining viral suppression and are associated with poor CD4+ T cell recovery Presented at:17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010 (Abstract 316).
106. Desai S, Landay A: Early immune senescence in HIV disease. Curr. HIV/AIDS Rep. 7(1), 4-10 (2010).
107. Boise LH, Minn AJ, Noel PJ et al.: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98.
108. J. Immunol. 185(7), 3788-3799 (2010).
109. Thompson CB, Lindsten T, Ledbetter JA et al.: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad. Sci. USA 86(4), 1333-1337 (1989). (Pubitemid 19061540)
110. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA: CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157(9), 3909-3917 (1996). (Pubitemid 126449299)
111. Frauwirth KA, Riley JL, Harris MH et al.: The CD28 signaling pathway regulates glucose metabolism. Immunity 16(6), 769-777 (2002). (Pubitemid 34786476)
112. Vallejo AN: CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol. Rev. 205, 158-169 (2005). (Pubitemid 40780184)
113. Choremi-Papadopoulou H, Panagiotou N, Samouilidou E et al.: CD28 costimulation and CD28 expression in T lymphocyte subsets in HIV-1 infection with and without progression to AIDS. Clin. Exp. Immunol. 119(3), 499-506 (2000). (Pubitemid 30146347)
114. + T cells are signifcant predictors for progression to AIDS. Clin. Exp. Immunol. 127(1), 137-144 (2002). (Pubitemid 34156973)
115. Kaplan RC, Sinclair E, Landay AL et al.: T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J. Infect. Dis. 203(4), 452-463 (2011).
116. + T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin. Immunol. 102(2), 154-161 (2002). (Pubitemid 34171514)
117. Lange CG, Lederman MM: Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. J. Antimicrobial Chemother. 51(1), 1-4 (2003). (Pubitemid 36163819)
118. + T cells in patients with HIV-1-HBV co-infections following HBV-active highly active antiretroviral therapy J. Virol. 84(6), 2657-2665 (2010).
119. Bourgarit A, Carcelain G, Samri A et al.: Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specifc CD4 Th1 cells and KIR-negative γδ T cells. J. Immunol. 183(6), 3915-3923 (2009).
120. Elliott J, Vohith K, Saramony S et al.: Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution infammatory syndrome during early antiretroviral therapy J. Infect. Dis. 200(11), 1736-1745 (2009).
121. + T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673-685 (2005). (Pubitemid 41248418)
122. Stone SF, Price P, Khan N, Moss PA, French MA: HIV patients on antiretroviral therapy have high frequencies of CD8 T cells specifc for immediate early protein-1 of cytomegalovirus. AIDS 19(6), 555-562 (2005). (Pubitemid 40543977)
123. + T cell recovery Clin. Immunol. 124(2), 200-206 (2007). (Pubitemid 47059044)
124. Naeger DM, Martin JN, Sinclair E et al.: Cytomegalovirus-specifc T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 5(1), e8886 (2010).
125. Hsue PY, Hunt PW, Sinclair E et al.: Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specifc T-cell responses. AIDS 20(18), 2275-2283 (2006). (Pubitemid 44789529)
126. + T cell recovery during antiretroviral therapy. Presented at:17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010 (Abstract 380).
127. Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J: Differential responses to interleukin 2 defne functionally distinct subsets of human natural killer cells. Eur. J. Immunol. 22(1), 1-6 (1992).
128. + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad. Sci. USA 102(8), 2886-2891 (2005). (Pubitemid 40299886)
129. Fogli M, Costa P, Murdaca G et al.: Signifcant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients. Eur. J. Immunol. 34(8), 2313-2321 (2004). (Pubitemid 39256113)
130. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G: Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 254(2), 149-154 (2009).
131. Alter G, Malenfant JM, Delabre RM et al.: Increased natural killer cell activity in viremic HIV-1 infection. J. Immunol. 173(8), 5305-5311 (2004). (Pubitemid 39387815)
132. Eller MA, Eller LA, Ouma BJ et al.: Elevated natural killer cell activity despite altered functional and phenotypic profle in Ugandans with HIV-1 clade A or clade D infection. J. Acquir. Immune Defc Syndr. 51(4), 380-389 (2009).
133. + cells and expansion of a population of CD 16dimCD56-cells with low lytic activity J. Acquir. Immune Defc Syndr. Hum Retrovirol 10(3), 331-340 (1995).
134. + natural killer cell subset during HIV infection. Cytometry 22(1), 10-15 (1995).
135. Plaeger-Marshall S, Spina CA, Giorgi JV et al.: Alterations in cytotoxic and phenotypic subsets of natural killer cells in acquired immune defciency syndrome (AIDS). J. Clin. Immunol. 7(1), 16-23 (1987). (Pubitemid 17028770)
136. Sirianni MC, Mezzaroma I, Aiuti F, Moretta A: Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodefciency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody Eur. J. Immunol. 24(8), 1874-1878 (1994). (Pubitemid 24237561)
137. Björkström NK, Ljunggren H-G, Sandberg JK: CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol. 31(11), 401-406 (2010).
138. Ward J, Barker E: Role of natural killer cells in HIV pathogenesis. Curr. HIV/AIDS Rep. 5(1), 44-50 (2008). (Pubitemid 351480781)
139. Brunetta E, Hudspeth KL, Mavilio D: Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J. Leukocyte Biol. 88(6), 1119-1130 (2010).
140. Villanueva JL, Caballero J, Del Nozal M et al.: Peripheral blood natural killer cell reconstitution after highly active antiretroviral therapy. AIDS 14(4), 473-474 (2000). (Pubitemid 30182453)
141. Chehimi J, Azzoni L, Farabaugh M et al.: Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J. Immunol. 179(4), 2642-2650 (2007).
142. + T cell in human immunodefciency virus infected patients during one-year antiretroviral therapy]. Zhonghua Nei Ke Za Zhi 47(9), 750-753 (2008).
143. Lichtfuss GF, Meehan AC, Cheng W-J et al.: Inhibition of early signal transduction events in NK cells which are important for antibody-dependent cellular cytotoxicity in both antiretroviral therapy naive HIV patients and patients receiving ART. Presented at: Keystone Symposium on NK and NKT Cell Biology: Specifcity and Redundancy of Innate Responses. Breckenridge, CO, USA, 9-14 January 2011 (Abstract 209).
144. Lichtfuss GF, Meehan AC, Cheng W-J et al.: HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J. Leukocyte Biol. 89(1), 149-158 (2010).
145. Liu Q, Sun Y, Rihn S et al.: Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodefciency virus type 1 infection. J. Virol. 83(17), 8705-8712 (2009).
146. + NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21(2), 356-359; author reply 359 (2007). (Pubitemid 46158133)
147. Ziegler-Heitbrock L, Ancuta P, Crowe S et al.: Nomenclature of monocytes and dendritic cells in blood. Blood 116(16), e74-e80 (2010).
148. + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178(10), 6581-6589 (2007). (Pubitemid 46717442)
149. + monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J. Infect. Dis. 196(1), 38-42 (2007). (Pubitemid 46982735)
150. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeffner-Cavaillon N: CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodefciency virus infection. Eur. J. Immunol. 25(12), 3418-3424 (1995).
151. + patients. Cytometry B Clin. Cytom. 72(1), 22-33 (2007). (Pubitemid 46105454)
152. Leatham EW, Bath PM, Tooze JA, Camm AJ: Increased monocyte tissue factor expression in coronary disease. Br. Heart J. 73(1), 10-13 (1995).
153. Crowe SM, Westhorpe CLV, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M: The macrophage: the intersection between HIV infection and atherosclerosis. J. Leukocyte Biol. 87(4), 589-598 (2010).
154. Maisa A, Westhorpe C, Elliott J et al.: Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus. HIV Ther. 4(6), 675-692 (2011).
155. Monforte ADA, Abrams D, Pradier C et al.: HIV-induced immunodefciency and mortality from AIDS-defning and non-AIDS-defning malignancies. AIDS 22(16), 2143-2153 (2008).
156. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr. Opin. HIV AIDS 5(6), 531-537 (2010).
157. Brown TT, Qaqish RB: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17), 2165-2174 (2006). (Pubitemid 44684707)
158. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G: Circulating levels of infammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J. Clin. Endocrinol. Metab. 93(5), 1952-1958 (2008). (Pubitemid 351656543)
159. Cauley JA, Danielson ME, Boudreau RM et al.: Infammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study J. Bone Miner. Res. 22(7), 1088-1095 (2007). (Pubitemid 351339731)
160. Group I-ES, Committee SS, Abrams D et al.: Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 361(16), 1548-1559 (2009).
161. Kaplan RC, Sinclair E, Landay AL et al.: T-cell senescence and T-cell activation predict carotid atherosclerosis in HIV-infected women. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010 (Abstract 709).